Stealth BioTherapeutics Announces Delay in FDA Action Date for Barth Syndrome Application Press Release / April 29, 2025April 29, 2025
Stealth BioTherapeutics to Present New Bevemipretide Data at ARVO Annual Meeting Press Release / April 24, 2025April 24, 2025
Stealth BioTherapeutics Announces Achievement of 50% Enrollment Target in Phase 3 ReNEW Study of Elamipretide in Patients with Dry Age-Related Macular Degeneration Press Release / March 13, 2025April 14, 2025
Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome Press Release / January 23, 2025April 14, 2025
